Cytomegalovirus (CMV) infection and early onset pre-eclampsia.


Cytomegalovirus (CMV) infection and early onset pre-eclampsia.

Introduction: Pre-eclampsia is one of the common gestational disorders characterized by hypertension after 20 weeks of gestation and proteinuria with unknown different etiologies. It is a major cause of maternal and perinatal morbidity and mortality. Human Cytomegalovirus (CMV) can affect uterine villuses and maternal spiral arteries. Therefore this study was designed to evaluate the potential link between Cytomegalovirus (CMV) infection and early onset pre-eclampsia. Materials and Methods: Thirty nine pregnant women with pre-eclampsia and forty healthy pregnant woman (as control group) were compared with each other in the term of demographic features and serum levels of IgM and IgG anti-CMV with an enzyme linked immunosorbent assay (ELISA). Also the avidity index for CMV IgG were evaluated and compared between two groups. Results: All the members of case and control groups were seronegative for anti-CMV IgM. Anti-CMV IgM and anti-CMV IgG status did not significantly differ between two groups (P=0.054 and P=0.151, respectively). Both the mean value of anti-CMV IgM serum levels and anti-CMV IgG avidity were not statistically different in patients with pre-eclampsia in comparison with control group (P=0.133 and P=0.238 respectively). Although all the enrolled individuals had positive anti-CMV IgG status, CMV IgG serum titer was lower in patients with pre-eclampsia compared to healthy subjects (174.35 vs. 208.65 Ru/ml, P=0.026). Conclusions: Lower level of anti-CMV IgG serum level in patients with pre-eclampsia represents decreased immune response to CMV infection which might have led to reactivation of chronic CMV infection and uterus vascular injury in the course of pregnancy

To more know more about the article :

How we work:

  • After submission, an acknowledgement with manuscript number is sent to the corresponding author within 7 working days.
  • A 21 day window time frame is allotted for peer-review process wherein multiple experts are contacted.
  • Author proof is generated within 7 working days after the acceptance decision.

Benefits on Publication:

Open Access: Permanent free access to your article upon publication ensures extensive global reach and readership.

Easy Article Sharing: Our open access enables you to share your article directly with colleagues through email and on social media via a single link, permitting third party reuse with appropriate citation in addition to the retention of content copyright by the author.

Global Marketing: Through promotion in a targeted global email announcement or press release, your article will be seen by thousands of the top-most thought-leaders in your field.

Color Art: In a world of black & white journal articles, high-quality full-color images make your article stand out from the crowd and tell a complete story, increasing readers and citations.

Social Media Exposure: Extended reach for your article through links on Twitter accounts provides maximum visibility worldwide.

Reprints: Distribute your work to colleagues and at conferences as we provide hard copy color reprints of your article on order.

Media Contact:
Nimmi Anna
Journal Manager
Allied Journal of Medical Research